TRACON Pharmaceuticals, Inc.
TCON · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.07 | 0.12 | 0.08 |
| FCF Yield | 64.40% | -84.24% | -47.33% | -16.24% |
| EV / EBITDA | 0.27 | -0.84 | -0.89 | -4.77 |
| Quality | ||||
| ROIC | -4,338.36% | -395.09% | -197.00% | -55.80% |
| Gross Margin | 99.88% | 0.00% | 95.95% | 0.00% |
| Cash Conversion Ratio | -1.02 | 0.90 | 0.79 | 1.02 |
| Growth | ||||
| Revenue 3-Year CAGR | 226.52% | – | – | -100.00% |
| Free Cash Flow Growth | 114.00% | -16.08% | -32.69% | 27.92% |
| Safety | ||||
| Net Debt / EBITDA | 1.10 | 0.27 | 0.80 | 1.70 |
| Interest Coverage | -0.94 | -28.06 | -89.14 | -29.77 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -66,325.71 | -89,493.44 | -128,871.07 | -52,468.75 |